{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:24:09Z","timestamp":1794407049849,"version":"4.9.0"},"reference-count":223,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Dis Primers"],"DOI":"10.1038\/s41572-025-00671-w","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T08:03:02Z","timestamp":1765440182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Podocytopathies"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1774-8088","authenticated-orcid":false,"given":"Paola","family":"Romagnani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6862-1941","authenticated-orcid":false,"given":"Sydney C. W.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Weins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7175-5062","authenticated-orcid":false,"given":"Tobias B.","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2648-626X","authenticated-orcid":false,"given":"Charlotte","family":"Osafo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-2956","authenticated-orcid":false,"given":"Hans-Joachim","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"671_CR1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1152\/physrev.00020.2002","volume":"83","author":"H Pavenstadt","year":"2003","unstructured":"Pavenstadt, H., Kriz, W. & Kretzler, M. Cell biology of the glomerular podocyte. Physiol. Rev. 83, 253\u2013307 (2003).","journal-title":"Physiol. Rev."},{"key":"671_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0196-7","volume":"6","author":"JB Kopp","year":"2020","unstructured":"Kopp, J. B. et al. Podocytopathies. Nat. Rev. Dis. Primers 6, 68 (2020).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"671_CR3","unstructured":"Tapia, C. & Bashir, K. Nephrotic syndrome (StatPearls, 2025)."},{"key":"671_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 100, S1\u2013S276 (2021).","journal-title":"Kidney Int."},{"key":"671_CR5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s10157-020-01946-0","volume":"24","author":"AS Levey","year":"2020","unstructured":"Levey, A. S. et al. Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. Clin. Exp. Nephrol. 24, 737\u2013747 (2020).","journal-title":"Clin. Exp. Nephrol."},{"key":"671_CR6","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1016\/j.kint.2024.11.007","volume":"107","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Nephrotic Syndrome In Children Work Group","year":"2025","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Nephrotic Syndrome In Children Work Group KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children. Kidney Int. 107, S241\u2013S289 (2025).","journal-title":"Kidney Int."},{"key":"671_CR7","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00467-022-05739-3","volume":"38","author":"A Trautmann","year":"2023","unstructured":"Trautmann, A. et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr. Nephrol. 38, 877\u2013919 (2023).","journal-title":"Pediatr. Nephrol."},{"key":"671_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00589-9","volume":"11","author":"P Romagnani","year":"2025","unstructured":"Romagnani, P. et al. Chronic kidney disease. Nat. Rev. Dis. Primers 11, 8 (2025).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"671_CR9","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1053\/j.ajkd.2018.04.021","volume":"72","author":"SH Saydah","year":"2018","unstructured":"Saydah, S. H. et al. Trends in albuminuria and GFR among adolescents in the United States, 1988-2014. Am. J. Kidney Dis. 72, 644\u2013652 (2018).","journal-title":"Am. J. Kidney Dis."},{"key":"671_CR10","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2215\/CJN.15011121","volume":"17","author":"S Hingorani","year":"2022","unstructured":"Hingorani, S. et al. Prevalence and risk factors for kidney disease and elevated BP in 2-year-old children born extremely premature. Clin. J. Am. Soc. Nephrol. 17, 1129\u20131138 (2022).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"671_CR11","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1007\/s11606-024-09185-9","volume":"40","author":"JL Bragg-Gresham","year":"2025","unstructured":"Bragg-Gresham, J. L. et al. Using risk assessment to improve screening for albuminuria among US adults without diabetes. J. Gen. Intern. Med. 40, 3159\u20133169 (2025).","journal-title":"J. Gen. Intern. Med."},{"key":"671_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0318736","volume":"20","author":"Q Xu","year":"2025","unstructured":"Xu, Q. et al. Association between cardiometabolic index and albuminuria: evidence from NHANES 2017-2020. PLoS ONE 20, e0318736 (2025).","journal-title":"PLoS ONE"},{"key":"671_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030131","volume":"13","author":"JI Barzilay","year":"2024","unstructured":"Barzilay, J. I., Farag, Y. M. K. & Durthaler, J. Albuminuria: an underappreciated risk factor for cardiovascular disease. J. Am. Heart Assoc. 13, e030131 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"671_CR14","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/ndt\/gfw079","volume":"32","author":"N Ebert","year":"2017","unstructured":"Ebert, N. et al. Prevalence of reduced kidney function and albuminuria in older adults: the Berlin Initiative study. Nephrol. Dial. Transpl. 32, 997\u20131005 (2017).","journal-title":"Nephrol. Dial. Transpl."},{"key":"671_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.26230","volume":"6","author":"CD Chu","year":"2023","unstructured":"Chu, C. D. et al. Estimated prevalence and testing for albuminuria in US adults at risk for chronic kidney disease. JAMA Netw. Open. 6, e2326230 (2023).","journal-title":"JAMA Netw. Open."},{"key":"671_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf122","author":"JMA Guerra","year":"2025","unstructured":"Guerra, J. M. A. & Martinez-Martinez, J. I. Multifactorial chronic kidney disease. Nephrol. Dial. Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfaf122 (2025).","journal-title":"Nephrol. Dial. Transplant."},{"key":"671_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/EDE.0000000000001576","volume":"34","author":"SV Vestergaard","year":"2023","unstructured":"Vestergaard, S. V. et al. Twenty-four-year trends in incidence and mortality of nephrotic syndrome: a population-based cohort study. Epidemiology 34, 411\u2013420 (2023).","journal-title":"Epidemiology"},{"key":"671_CR18","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2215\/CJN.05000516","volume":"12","author":"M Vivarelli","year":"2017","unstructured":"Vivarelli, M. et al. Minimal change disease. Clin. J. Am. Soc. Nephrol. 12, 332\u2013345 (2017).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"671_CR19","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1053\/j.ajkd.2016.03.416","volume":"68","author":"JJ Sim","year":"2016","unstructured":"Sim, J. J. et al. Distribution of biopsy-proven presumed primary glomerulonephropathies in 2000-2011 among a racially and ethnically diverse US population. Am. J. Kidney Dis. 68, 533\u2013544 (2016).","journal-title":"Am. J. Kidney Dis."},{"key":"671_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2215\/CJN.0000000590","volume":"20","author":"MA Munis","year":"2024","unstructured":"Munis, M. A. et al. Incidence and proportion of primary focal segmental glomerulosclerosis (FSGS) among a racially and ethnically diverse adult patient population between 2010 and 2021. Clin. J. Am. Soc. Nephrol. 20, 229\u2013238 (2024).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"671_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100760","volume":"6","author":"ME Bensink","year":"2024","unstructured":"Bensink, M. E. et al. Kidney failure attributed to focal segmental glomerulosclerosis: a USRDS retrospective cohort study of epidemiology, treatment modalities, and economic burden. Kidney Med. 6, 100760 (2024).","journal-title":"Kidney Med."},{"key":"671_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00303-z","volume":"7","author":"P Ronco","year":"2021","unstructured":"Ronco, P. et al. Membranous nephropathy. Nat. Rev. Dis. Primers 7, 69 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"671_CR23","doi-asserted-by":"publisher","first-page":"798","DOI":"10.2215\/CJN.14321121","volume":"17","author":"JT Brandenburg","year":"2022","unstructured":"Brandenburg, J. T. et al. Apolipoprotein L1 high-risk genotypes and albuminuria in sub-Saharan African populations. Clin. J. Am. Soc. Nephrol. 17, 798\u2013808 (2022).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"671_CR24","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1007\/s00467-022-05850-5","volume":"38","author":"V Gracchi","year":"2023","unstructured":"Gracchi, V. et al. Longitudinal relationship between albuminuria in infancy and childhood. Pediatr. Nephrol. 38, 2897\u20132900 (2023).","journal-title":"Pediatr. Nephrol."},{"key":"671_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf092","author":"J Halbritter","year":"2025","unstructured":"Halbritter, J. et al. Chronic kidney disease of unexplained cause (CKDx): a consensus statement by the Genes & Kidney Working Group of the ERA. Nephrol. Dial. Transpl. https:\/\/doi.org\/10.1093\/ndt\/gfaf092 (2025).","journal-title":"Nephrol. Dial. Transpl."},{"key":"671_CR26","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0002-9440(10)64421-5","volume":"161","author":"MA Saleem","year":"2002","unstructured":"Saleem, M. A. et al. Co-localization of nephrin, podocin, and the actin cytoskeleton: evidence for a role in podocyte foot process formation. Am. J. Pathol. 161, 1459\u20131466 (2002).","journal-title":"Am. J. Pathol."},{"key":"671_CR27","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1681\/ASN.0000000697","volume":"36","author":"ME Melica","year":"2025","unstructured":"Melica, M. E. et al. Piezo1, F-actin remodeling, and podocyte survival and regeneration. J. Am. Soc. Nephrol. 36, 1749\u20131763 (2025).","journal-title":"J. Am. Soc. Nephrol."},{"key":"671_CR28","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1681\/ASN.2008101117","volume":"20","author":"H Fukasawa","year":"2009","unstructured":"Fukasawa, H. et al. Slit diaphragms contain tight junction proteins. J. Am. Soc. Nephrol. 20, 1491\u20131503 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"671_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2174\/156652413804486250","volume":"13","author":"L Lasagni","year":"2013","unstructured":"Lasagni, L. et al. Podocyte mitosis \u2014 a catastrophe. Curr. Mol. Med. 13, 13\u201323 (2013).","journal-title":"Curr. Mol. Med."},{"key":"671_CR30","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/path.4193","volume":"230","author":"SR Mulay","year":"2013","unstructured":"Mulay, S. R. et al. Podocyte loss involves MDM2-driven mitotic catastrophe. J. Pathol. 230, 322\u2013335 (2013).","journal-title":"J. Pathol."},{"key":"671_CR31","doi-asserted-by":"publisher","DOI":"10.1172\/JCI171237","volume":"133","author":"X Tian","year":"2023","unstructured":"Tian, X. et al. Profilin1 is required for prevention of mitotic catastrophe in murine and human glomerular diseases. J. Clin. Invest. 133, e171237 (2023).","journal-title":"J. Clin. Invest."},{"key":"671_CR32","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1172\/JCI39492","volume":"120","author":"B Hartleben","year":"2010","unstructured":"Hartleben, B. et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J. Clin. Invest. 120, 1084\u20131096 (2010).","journal-title":"J. Clin. Invest."},{"key":"671_CR33","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1681\/ASN.2016050519","volume":"28","author":"S Zschiedrich","year":"2017","unstructured":"Zschiedrich, S. et al. Targeting mTOR signaling can prevent the progression of FSGS. J. Am. Soc. Nephrol. 28, 2144\u20132157 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"671_CR34","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1681\/ASN.2013050452","volume":"25","author":"N Wanner","year":"2014","unstructured":"Wanner, N. et al. Unraveling the role of podocyte turnover in glomerular aging and injury. J. Am. Soc. Nephrol. 25, 707\u2013716 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"671_CR35","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.stemcr.2015.07.003","volume":"5","author":"L Lasagni","year":"2015","unstructured":"Lasagni, L. et al. Podocyte regeneration driven by renal progenitors determines glomerular disease remission and can be pharmacologically enhanced. Stem Cell Rep. 5, 248\u2013263 (2015).","journal-title":"Stem Cell Rep."},{"key":"671_CR36","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1126\/science.adp4629","volume":"389","author":"C Conte","year":"2025","unstructured":"Conte, C. et al. Estrogen-regulated renal progenitors determine pregnancy adaptation and preeclampsia. Science 389, 1016\u20131023 (2025). This study provides evidence that pre-eclampsia may represent an adaptive podocytopathy related to inefficient generation of new podocytes by renal progenitor cells.","journal-title":"Science"},{"key":"671_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg3277","volume":"14","author":"ME Melica","year":"2022","unstructured":"Melica, M. E. et al. Differentiation of crescent-forming kidney progenitor cells into podocytes attenuates severe glomerulonephritis in mice. Sci. Transl. Med. 14, eabg3277 (2022).","journal-title":"Sci. Transl. Med."},{"key":"671_CR38","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.kint.2018.08.013","volume":"94","author":"S Romoli","year":"2018","unstructured":"Romoli, S. et al. CXCL12 blockade preferentially regenerates lost podocytes in cortical nephrons by targeting an intrinsic podocyte-progenitor feedback mechanism. Kidney Int. 94, 1111\u20131126 (2018).","journal-title":"Kidney Int."},{"key":"671_CR39","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.kint.2023.03.036","volume":"104","author":"WB Liu","year":"2023","unstructured":"Liu, W. B. et al. Single cell landscape of parietal epithelial cells in healthy and diseased states. Kidney Int. 104, 108\u2013123 (2023).","journal-title":"Kidney Int."},{"key":"671_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.838272","volume":"10","author":"F Ravaglia","year":"2022","unstructured":"Ravaglia, F. et al. The pathology lesion patterns of podocytopathies: how and why? Front. Cell Dev. Biol. 10, 838272 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"671_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1681\/ASN.2019111195","volume":"31","author":"LH Beck Jr.","year":"2020","unstructured":"Beck, L. H. Jr. & Salant, D. J. Refining our understanding of the PLA2R-antibody response in primary membranous nephropathy: looking forward, looking back. J. Am. Soc. Nephrol. 31, 8\u201311 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"671_CR42","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/ndt\/gfad227","volume":"39","author":"S Sethi","year":"2024","unstructured":"Sethi, S. & Fervenza, F. C. Membranous nephropathy \u2014 diagnosis and identification of target antigens. Nephrol. Dial. Transpl. 39, 600\u2013606 (2024).","journal-title":"Nephrol. Dial. Transpl."},{"key":"671_CR43","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa2314471","volume":"391","author":"FE Hengel","year":"2024","unstructured":"Hengel, F. E. et al. Autoantibodies targeting nephrin in podocytopathies. N. Engl. J. Med. 391, 422\u2013433 (2024). This study established robust validation and clinical generalizability of anti-nephrin autoimmunity in a large multicentre study across different types of podocytopathies.","journal-title":"N. Engl. J. Med."},{"key":"671_CR44","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1681\/ASN.2021060794","volume":"33","author":"AJB Watts","year":"2022","unstructured":"Watts, A. J. B. et al. Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J. Am. Soc. Nephrol. 33, 238\u2013252 (2022). The key study providing strong clinical evidence that a subset of minimal change disease is autoimmune, identifying circulating anti-nephrin antibodies that correlate with disease activity.","journal-title":"J. Am. Soc. Nephrol."},{"key":"671_CR45","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1681\/ASN.0000000642","volume":"36","author":"V Raglianti","year":"2025","unstructured":"Raglianti, V. et al. Anti-slit antibodies against podocin and Kirrel1 in pediatric and adult podocytopathies. J. Am. Soc. Nephrol. 36, 702\u2013705 (2025). This study provided evidence that autoimmunity in podocytopathies involves multiple antigens of the slit diaphragm, beyond nephrin.","journal-title":"J. Am. Soc. Nephrol."},{"key":"671_CR46","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/00007890-200202150-00013","volume":"73","author":"J Patrakka","year":"2002","unstructured":"Patrakka, J. et al. Recurrence of nephrotic syndrome in kidney grafts of patients with congenital nephrotic syndrome of the Finnish type: role of nephrin. Transplantation 73, 394\u2013403 (2002).","journal-title":"Transplantation"},{"key":"671_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf156","author":"V Raglianti","year":"2025","unstructured":"Raglianti, V. et al. Anti-nephrin, anti-podocin and anti-Kirrel1 antibodies: biological challenges and clinical implications. Nephrol. Dial. Transpl. https:\/\/doi.org\/10.1093\/ndt\/gfaf156 (2025).","journal-title":"Nephrol. Dial. Transpl."},{"key":"671_CR48","doi-asserted-by":"publisher","DOI":"10.1172\/JCI186769","volume":"135","author":"FE Hengel","year":"2025","unstructured":"Hengel, F. E. et al. Passive transfer of patient-derived anti-nephrin autoantibodies causes a podocytopathy with minimal change lesions. J. Clin. Invest. 135, e186769 (2025).","journal-title":"J. Clin. Invest."},{"key":"671_CR49","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.kint.2024.09.006","volume":"106","author":"V Raglianti","year":"2024","unstructured":"Raglianti, V. et al. Anti-slit diaphragm antibodies on kidney biopsy identify pediatric patients with steroid-resistant nephrotic syndrome responsive to second-line immunosuppressants. Kidney Int. 106, 1124\u20131134 (2024).","journal-title":"Kidney Int."},{"key":"671_CR50","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.kint.2023.11.022","volume":"105","author":"Y Shirai","year":"2024","unstructured":"Shirai, Y. et al. A multi-institutional study found a possible role of anti-nephrin antibodies in post-transplant focal segmental glomerulosclerosis recurrence. Kidney Int. 105, 608\u2013617 (2024).","journal-title":"Kidney Int."},{"key":"671_CR51","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.kint.2024.07.022","volume":"106","author":"I Batal","year":"2024","unstructured":"Batal, I. et al. Pre-transplant anti-nephrin antibodies are specific predictors of recurrent diffuse podocytopathy in the kidney allograft. Kidney Int. 106, 749\u2013752 (2024).","journal-title":"Kidney Int."},{"key":"671_CR52","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.kint.2025.01.019","volume":"107","author":"FE Hengel","year":"2025","unstructured":"Hengel, F. E. et al. Anti-nephrin autoantibodies in steroid-resistant nephrotic syndrome may inform treatment strategy. Kidney Int. 107, 1099\u20131103 (2025).","journal-title":"Kidney Int."},{"key":"671_CR53","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1172\/JCI7728","volume":"104","author":"PS Topham","year":"1999","unstructured":"Topham, P. S. et al. Nephritogenic mAb 5-1-6 is directed at the extracellular domain of rat nephrin. J. Clin. Invest. 104, 1559\u20131566 (1999).","journal-title":"J. Clin. Invest."},{"key":"671_CR54","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf100","volume":"18","author":"FE Hengel","year":"2025","unstructured":"Hengel, F. E., Huber, T. B. & Tomas, N. M. Potential and pitfalls of measuring circulating anti-nephrin autoantibodies in glomerular diseases. Clin. Kidney J. 18, sfaf100 (2025).","journal-title":"Clin. Kidney J."},{"key":"671_CR55","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1016\/j.ekir.2025.07.003","volume":"10","author":"VC Raglianti","year":"2025","unstructured":"Raglianti, V. C. et al. Anti-podocin enzyme-linked immunosorbent assay guides immunotherapy in steroid-resistant nephrotic syndrome. Kidney Int. Rep. 10, 3689\u20133693 (2025).","journal-title":"Kidney Int. Rep."},{"key":"671_CR56","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.kint.2025.06.012","volume":"108","author":"Y Shirai","year":"2025","unstructured":"Shirai, Y. et al. A case of post-transplant recurrent focal segmental glomerulosclerosis: graft biopsy showing IgG colocalization with nephrin, podocin, and Kirrel1. Kidney Int. 108, 714\u2013715 (2025).","journal-title":"Kidney Int."},{"key":"671_CR57","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.20257qdwq9g8","author":"Y Shirai","year":"2025","unstructured":"Shirai, Y. et al. Analysis of multiple autoantibodies in post-transplant recurrent FSGS. J. Am. Soc. Nephrol. https:\/\/doi.org\/10.1681\/ASN.20257qdwq9g8 (2025).","journal-title":"J. Am. Soc. Nephrol."},{"key":"671_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15383-w","volume":"11","author":"J Xie","year":"2020","unstructured":"Xie, J. et al. The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nat. Commun. 11, 1600 (2020).","journal-title":"Nat. Commun."},{"key":"671_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37985-w","volume":"14","author":"A Barry","year":"2023","unstructured":"Barry, A. et al. Multi-population genome-wide association study implicates immune and non-immune factors in pediatric steroid-sensitive nephrotic syndrome. Nat. Commun. 14, 2481 (2023).","journal-title":"Nat. Commun."},{"key":"671_CR60","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1053\/j.akdh.2024.04.001","volume":"31","author":"EB Caparali","year":"2024","unstructured":"Caparali, E. B., De Gregorio, V. & Barua, M. Genetic causes of nephrotic syndrome and focal and segmental glomerulosclerosis. Adv. Kidney Dis. Health 31, 309\u2013316 (2024).","journal-title":"Adv. Kidney Dis. Health"},{"key":"671_CR61","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/00041552-200107000-00009","volume":"10","author":"K Tryggvason","year":"2001","unstructured":"Tryggvason, K. & Wartiovaara, J. Molecular basis of glomerular permselectivity. Curr. Opin. Nephrol. Hypertens. 10, 543\u2013549 (2001).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"671_CR62","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1681\/ASN.2009040379","volume":"20","author":"G Mollet","year":"2009","unstructured":"Mollet, G. et al. Podocin inactivation in mature kidneys causes focal segmental glomerulosclerosis and nephrotic syndrome. J. Am. Soc. Nephrol. 20, 2181\u20132189 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"671_CR63","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/ng.2898","volume":"46","author":"K Tory","year":"2014","unstructured":"Tory, K. et al. Mutation-dependent recessive inheritance of NPHS2-associated steroid-resistant nephrotic syndrome. Nat. Genet. 46, 299\u2013304 (2014).","journal-title":"Nat. Genet."},{"key":"671_CR64","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.kint.2020.08.035","volume":"99","author":"J Matsuda","year":"2021","unstructured":"Matsuda, J. et al. Rho GTPase regulatory proteins in podocytes. Kidney Int. 99, 336\u2013345 (2021).","journal-title":"Kidney Int."},{"key":"671_CR65","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1007\/s00467-020-04812-z","volume":"36","author":"S Sever","year":"2021","unstructured":"Sever, S. Role of actin cytoskeleton in podocytes. Pediatr. Nephrol. 36, 2607\u20132614 (2021).","journal-title":"Pediatr. Nephrol."},{"key":"671_CR66","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adr1017","volume":"10","author":"B Subramanian","year":"2024","unstructured":"Subramanian, B. et al. INF2 mutations cause kidney disease through a gain-of-function mechanism. Sci. Adv. 10, eadr1017 (2024).","journal-title":"Sci. Adv."},{"key":"671_CR67","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1681\/ASN.0000000501","volume":"36","author":"B Wooden","year":"2025","unstructured":"Wooden, B. et al. Natural history and clinicopathological associations of TRPC6-associated podocytopathy. J. Am. Soc. Nephrol. 36, 274\u2013289 (2025).","journal-title":"J. Am. Soc. Nephrol."},{"key":"671_CR68","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/ki.2015.198","volume":"88","author":"L Dong","year":"2015","unstructured":"Dong, L., Pietsch, S. & Englert, C. Towards an understanding of kidney diseases associated with WT1 mutations. Kidney Int. 88, 684\u2013690 (2015).","journal-title":"Kidney Int."},{"key":"671_CR69","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00467-016-3462-x","volume":"32","author":"Y Harita","year":"2017","unstructured":"Harita, Y. et al. Spectrum of LMX1B mutations: from nail\u2013patella syndrome to isolated nephropathy. Pediatr. Nephrol. 32, 1845\u20131850 (2017).","journal-title":"Pediatr. Nephrol."},{"key":"671_CR70","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1681\/ASN.2013070686","volume":"25","author":"M Barua","year":"2014","unstructured":"Barua, M. et al. Mutations in PAX2 associate with adult-onset FSGS. J. Am. Soc. Nephrol. 25, 1942\u20131953 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"671_CR71","doi-asserted-by":"publisher","first-page":"F704","DOI":"10.1152\/ajprenal.00259.2023","volume":"326","author":"J Cunanan","year":"2024","unstructured":"Cunanan, J. et al. Mice with a Pax2 missense variant display impaired glomerular repair. Am. J. Physiol. Ren. Physiol. 326, F704\u2013F726 (2024).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"671_CR72","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.kint.2022.04.029","volume":"102","author":"S Drovandi","year":"2022","unstructured":"Drovandi, S. et al. Oral Coenzyme Q10 supplementation leads to better preservation of kidney function in steroid-resistant nephrotic syndrome due to primary coenzyme Q10 deficiency. Kidney Int. 102, 604\u2013612 (2022).","journal-title":"Kidney Int."},{"key":"671_CR73","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2404211","volume":"392","author":"RA Gbadegesin","year":"2025","unstructured":"Gbadegesin, R. A. et al. APOL1 bi- and monoallelic variants and chronic kidney disease in West Africans. N. Engl. J. Med. 392, 228\u2013238 (2025).","journal-title":"N. Engl. J. Med."},{"key":"671_CR74","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev-physiol-021119-034345","volume":"82","author":"DJ Friedman","year":"2020","unstructured":"Friedman, D. J. & Pollak, M. R. APOL1 and kidney disease: from genetics to biology. Annu. Rev. Physiol. 82, 323\u2013342 (2020).","journal-title":"Annu. Rev. Physiol."},{"key":"671_CR75","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172262","volume":"134","author":"S Datta","year":"2024","unstructured":"Datta, S. et al. APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease. J. Clin. Invest. 134, e172262 (2024).","journal-title":"J. Clin. Invest."},{"key":"671_CR76","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.kint.2023.03.035","volume":"104","author":"S Grampp","year":"2023","unstructured":"Grampp, S. et al. Hypoxia hits APOL1 in the kidney. Kidney Int. 104, 53\u201360 (2023).","journal-title":"Kidney Int."},{"key":"671_CR77","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1681\/ASN.0000000000000219","volume":"34","author":"AM Hung","year":"2023","unstructured":"Hung, A. M. et al. Genetic inhibition of APOL1 pore-forming function prevents APOL1-mediated kidney disease. J. Am. Soc. Nephrol. 34, 1889\u20131899 (2023). This study demonstrates that blocking APOL1 pore-forming activity can prevent kidney injury, directly linking pathogenic mechanism to therapeutic strategy for APOL1-mediated kidney disease.","journal-title":"J. Am. Soc. Nephrol."},{"key":"671_CR78","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2215\/CJN.06060519","volume":"15","author":"S Landini","year":"2020","unstructured":"Landini, S. et al. Reverse phenotyping after whole-exome sequencing in steroid-resistant nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 15, 89\u2013100 (2020).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"671_CR79","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2215\/CJN.04230321","volume":"17","author":"J Savige","year":"2022","unstructured":"Savige, J. et al. Guidelines for genetic testing and management of Alport syndrome. Clin. J. Am. Soc. Nephrol. 17, 143\u2013154 (2022).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"671_CR80","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1172\/JCI129937","volume":"130","author":"M Bedin","year":"2020","unstructured":"Bedin, M. et al. Human C-terminal CUBN variants associate with chronic proteinuria and normal renal function. J. Clin. Invest. 130, 335\u2013344 (2020).","journal-title":"J. Clin. Invest."},{"key":"671_CR81","doi-asserted-by":"publisher","first-page":"242","DOI":"10.7326\/0003-4819-147-4-200708210-00006","volume":"147","author":"WA Gahl","year":"2007","unstructured":"Gahl, W. A., Balog, J. Z. & Kleta, R. Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy. Ann. Intern. Med. 147, 242\u2013250 (2007).","journal-title":"Ann. Intern. Med."},{"key":"671_CR82","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/MOP.0000000000000603","volume":"30","author":"KJ Reidy","year":"2018","unstructured":"Reidy, K. J., Hjorten, R. & Parekh, R. S. Genetic risk of APOL1 and kidney disease in children and young adults of African ancestry. Curr. Opin. Pediatr. 30, 252\u2013259 (2018).","journal-title":"Curr. Opin. Pediatr."},{"key":"671_CR83","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-022-00559-y","volume":"18","author":"M Cortinovis","year":"2022","unstructured":"Cortinovis, M. et al. Glomerular hyperfiltration. Nat. Rev. Nephrol. 18, 435\u2013451 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"671_CR84","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.kint.2021.06.040","volume":"100","author":"L Butt","year":"2021","unstructured":"Butt, L. et al. A mathematical estimation of the physical forces driving podocyte detachment. Kidney Int. 100, 1054\u20131062 (2021).","journal-title":"Kidney Int."},{"key":"671_CR85","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1681\/ASN.2017020174","volume":"28","author":"R Nishizono","year":"2017","unstructured":"Nishizono, R. et al. FSGS as an adaptive response to growth-induced podocyte stress. J. Am. Soc. Nephrol. 28, 2931\u20132945 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"671_CR86","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1056\/NEJMoa1614329","volume":"376","author":"A Denic","year":"2017","unstructured":"Denic, A. et al. Single-nephron glomerular filtration rate in healthy adults. N. Engl. J. Med. 376, 2349\u20132357 (2017).","journal-title":"N. Engl. J. Med."},{"key":"671_CR87","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.kint.2023.12.018","volume":"105","author":"GB Piccoli","year":"2024","unstructured":"Piccoli, G. B. et al. Any reduction in maternal kidney mass makes a difference during pregnancy in gestational and fetal outcome. Kidney Int. 105, 865\u2013876 (2024).","journal-title":"Kidney Int."},{"key":"671_CR88","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.2215\/CJN.05940614","volume":"9","author":"VD Garovic","year":"2014","unstructured":"Garovic, V. D. The role of the podocyte in preeclampsia. Clin. J. Am. Soc. Nephrol. 9, 1337\u20131340 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"671_CR89","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1681\/ASN.2016111202","volume":"28","author":"SI Gilani","year":"2017","unstructured":"Gilani, S. I. et al. Urinary extracellular vesicles of podocyte origin and renal injury in preeclampsia. J. Am. Soc. Nephrol. 28, 3363\u20133372 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"671_CR90","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1093\/ndt\/gfaf051","volume":"40","author":"P Romagnani","year":"2025","unstructured":"Romagnani, P. SGLT2 Inhibitors in CKD: are they really effective in all patients? Nephrol. Dial. Transpl. 40, 1838\u20131842 (2025).","journal-title":"Nephrol. Dial. Transpl."},{"key":"671_CR91","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1681\/ASN.2015050515","volume":"27","author":"Y Lu","year":"2016","unstructured":"Lu, Y. et al. Macula densa nitric oxide synthase 1\u03b2 protects against salt-sensitive hypertension. J. Am. Soc. Nephrol. 27, 2346\u20132356 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"671_CR92","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41581-022-00540-9","volume":"18","author":"KI Ataga","year":"2022","unstructured":"Ataga, K. I., Saraf, S. L. & Derebail, V. K. The nephropathy of sickle cell trait and sickle cell disease. Nat. Rev. Nephrol. 18, 361\u2013377 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"671_CR93","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.kint.2023.11.034","volume":"105","author":"ML Alcalde-Ortiz","year":"2024","unstructured":"Alcalde-Ortiz, M. L. et al. Pediatric kidney dimensions and risk of persistent albuminuria in Mexican adolescents. Kidney Int. 105, 824\u2013834 (2024).","journal-title":"Kidney Int."},{"key":"671_CR94","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nrneph.2011.1","volume":"7","author":"E Ritz","year":"2011","unstructured":"Ritz, E. et al. Prenatal programming \u2014 effects on blood pressure and renal function. Nat. Rev. Nephrol. 7, 137\u2013144 (2011).","journal-title":"Nat. Rev. Nephrol."},{"key":"671_CR95","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.34067\/KID.0000000000000284","volume":"4","author":"SJ Shankland","year":"2023","unstructured":"Shankland, S. J. et al. Podocyte senescence and aging. Kidney360 4, 1784\u20131793 (2023).","journal-title":"Kidney360"},{"key":"671_CR96","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1681\/ASN.2018030296","volume":"30","author":"AC Ricardo","year":"2019","unstructured":"Ricardo, A. C. et al. Sex-related disparities in CKD progression. J. Am. Soc. Nephrol. 30, 137\u2013146 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"671_CR97","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41581-023-00784-z","volume":"20","author":"NC Chesnaye","year":"2024","unstructured":"Chesnaye, N. C. et al. Differences in the epidemiology, management and outcomes of kidney disease in men and women. Nat. Rev. Nephrol. 20, 7\u201320 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"671_CR98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092693","volume":"9","author":"WM White","year":"2014","unstructured":"White, W. M. et al. Persistent urinary podocyte loss following preeclampsia may reflect subclinical renal injury. PLoS ONE 9, e92693 (2014).","journal-title":"PLoS ONE"},{"key":"671_CR99","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.kint.2023.04.030","volume":"104","author":"VD Garovic","year":"2023","unstructured":"Garovic, V. D. & Piccoli, G. B. A kidney-centric view of pre-eclampsia through the kidney\u2013placental bidirectional lens. Kidney Int. 104, 213\u2013217 (2023).","journal-title":"Kidney Int."},{"key":"671_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-023-00417-6","volume":"9","author":"E Dimitriadis","year":"2023","unstructured":"Dimitriadis, E. et al. Pre-eclampsia. Nat. Rev. Dis. Primers 9, 8 (2023).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"671_CR101","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1056\/NEJMoa031884","volume":"350","author":"RJ Levine","year":"2004","unstructured":"Levine, R. J. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672\u2013683 (2004).","journal-title":"N. Engl. J. Med."},{"key":"671_CR102","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1056\/NEJMc2011400","volume":"383","author":"VG Puelles","year":"2020","unstructured":"Puelles, V. G. et al. Multiorgan and renal tropism of SARS-CoV-2. N. Engl. J. Med. 383, 590\u2013592 (2020).","journal-title":"N. Engl. J. Med."},{"key":"671_CR103","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.kint.2022.02.031","volume":"101","author":"L Lodi","year":"2022","unstructured":"Lodi, L. et al. Type I interferon-related kidney disorders. Kidney Int. 101, 1142\u20131159 (2022).","journal-title":"Kidney Int."},{"key":"671_CR104","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ajpath.2013.04.017","volume":"183","author":"A Migliorini","year":"2013","unstructured":"Migliorini, A. et al. The antiviral cytokines IFN-\u03b1 and IFN-\u03b2 modulate parietal epithelial cells and promote podocyte loss: implications for IFN toxicity, viral glomerulonephritis, and glomerular regeneration. Am. J. Pathol. 183, 431\u2013440 (2013).","journal-title":"Am. J. Pathol."},{"key":"671_CR105","doi-asserted-by":"publisher","DOI":"10.1172\/JCI136329","volume":"131","author":"J Wu","year":"2021","unstructured":"Wu, J. et al. The key role of NLRP3 and STING in APOL1-associated podocytopathy. J. Clin. Invest. 131, e136329 (2021).","journal-title":"J. Clin. Invest."},{"key":"671_CR106","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11904-023-00645-1","volume":"20","author":"CE Cervantes","year":"2023","unstructured":"Cervantes, C. E. & Atta, M. G. Updates on HIV and kidney disease. Curr. HIV\/AIDS Rep. 20, 100\u2013110 (2023).","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"671_CR107","volume":"2012","author":"E Kwiatkowska","year":"2012","unstructured":"Kwiatkowska, E. et al. Minimal-change disease secondary to Borrelia burgdorferi infection. Case Rep. Nephrol. 2012, 294532 (2012).","journal-title":"Case Rep. Nephrol."},{"key":"671_CR108","doi-asserted-by":"publisher","first-page":"964","DOI":"10.2215\/CJN.00590120","volume":"15","author":"A Amoura","year":"2020","unstructured":"Amoura, A. et al. Malaria, collapsing glomerulopathy, and focal and segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 15, 964\u2013972 (2020).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"671_CR109","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.therap.2023.10.010","volume":"79","author":"AS Garnier","year":"2024","unstructured":"Garnier, A. S., Laubacher, H. & Briet, M. Drug-induced glomerular diseases. Therapie 79, 271\u2013281 (2024).","journal-title":"Therapie"},{"key":"671_CR110","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.kint.2018.02.003","volume":"94","author":"CJ Sperati","year":"2018","unstructured":"Sperati, C. J. & Rosenberg, A. Z. Hydroxychloroquine-induced mimic of renal Fabry disease. Kidney Int. 94, 634 (2018).","journal-title":"Kidney Int."},{"key":"671_CR111","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1093\/ndt\/gfae184","volume":"39","author":"EB Barbir","year":"2024","unstructured":"Barbir, E. B., Kitchlu, A. & Herrmann, S. M. Immune checkpoint inhibitor-associated nephritis-treatment standard. Nephrol. Dial. Transpl. 39, 1785\u20131798 (2024).","journal-title":"Nephrol. Dial. Transpl."},{"key":"671_CR112","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MD.0000000000000207","volume":"93","author":"H Izzedine","year":"2014","unstructured":"Izzedine, H. et al. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine 93, 333\u2013339 (2014).","journal-title":"Medicine"},{"key":"671_CR113","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/ckj\/sfab176","volume":"15","author":"A Ribas","year":"2022","unstructured":"Ribas, A. et al. Podocytopathy in patients with monoclonal gammopathy: three patients and literature review. Clin. Kidney J. 15, 417\u2013424 (2022).","journal-title":"Clin. Kidney J."},{"key":"671_CR114","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.kint.2022.11.026","volume":"103","author":"SH Nasr","year":"2023","unstructured":"Nasr, S. H. et al. Pathological characteristics of light chain crystalline podocytopathy. Kidney Int. 103, 616\u2013626 (2023).","journal-title":"Kidney Int."},{"key":"671_CR115","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.kint.2024.02.027","volume":"106","author":"SH Nasr","year":"2024","unstructured":"Nasr, S. H. et al. Monoclonal immunoglobulin crystalline nephropathies. Kidney Int. 106, 201\u2013213 (2024).","journal-title":"Kidney Int."},{"key":"671_CR116","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1159\/000544759","volume":"56","author":"S Kelddal","year":"2025","unstructured":"Kelddal, S. et al. Edema and outcome in patients with nephrotic-range albuminuria and hypoalbuminemia: a Danish multicenter cohort study. Am. J. Nephrol. 56, 510\u2013519 (2025).","journal-title":"Am. J. Nephrol."},{"key":"671_CR117","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00467-013-2567-8","volume":"29","author":"MA Cadnapaphornchai","year":"2014","unstructured":"Cadnapaphornchai, M. A. et al. The nephrotic syndrome: pathogenesis and treatment of edema formation and secondary complications. Pediatr. Nephrol. 29, 1159\u20131167 (2014).","journal-title":"Pediatr. Nephrol."},{"key":"671_CR118","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1007\/s11033-021-06967-w","volume":"49","author":"M Awazu","year":"2022","unstructured":"Awazu, M. Structural and functional changes in the kidney caused by adverse fetal and neonatal environments. Mol. Biol. Rep. 49, 2335\u20132344 (2022).","journal-title":"Mol. Biol. Rep."},{"key":"671_CR119","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S0140-6736(17)30576-7","volume":"390","author":"VA Luyckx","year":"2017","unstructured":"Luyckx, V. A. et al. A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group. Lancet 390, 424\u2013428 (2017).","journal-title":"Lancet"},{"key":"671_CR120","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00467-022-05663-6","volume":"38","author":"Q Gao","year":"2023","unstructured":"Gao, Q. et al. Urine podocyte mRNA loss in preterm infants and related perinatal risk factors. Pediatr. Nephrol. 38, 729\u2013738 (2023).","journal-title":"Pediatr. Nephrol."},{"key":"671_CR121","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.kint.2019.12.015","volume":"97","author":"O Gross","year":"2020","unstructured":"Gross, O. et al. A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport\u2019s syndrome. Kidney Int. 97, 1275\u20131286 (2020).","journal-title":"Kidney Int."},{"key":"671_CR122","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1681\/ASN.0000000000000076","volume":"34","author":"F Becherucci","year":"2023","unstructured":"Becherucci, F. et al. A clinical workflow for cost-saving high-rate diagnosis of genetic kidney diseases. J. Am. Soc. Nephrol. 34, 706\u2013720 (2023).","journal-title":"J. Am. Soc. Nephrol."},{"key":"671_CR123","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1093\/ndt\/gfae055","volume":"39","author":"KR Tuttle","year":"2024","unstructured":"Tuttle, K. R. CKD screening for better kidney health: why? Who? How? When? Nephrol. Dial. Transpl. 39, 1537\u20131539 (2024).","journal-title":"Nephrol. Dial. Transpl."},{"key":"671_CR124","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0022-3476(82)80287-4","volume":"101","author":"VM Vehaskari","year":"1982","unstructured":"Vehaskari, V. M. & Rapola, J. Isolated proteinuria: analysis of a school-age population. J. Pediatr. 101, 661\u2013668 (1982).","journal-title":"J. Pediatr."},{"key":"671_CR125","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.cmi.2024.12.007","volume":"31","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Performance of molecular tests for diagnosis of bloodstream infections in the clinical setting: a systematic literature review and meta-analysis. Clin. Microbiol. Infect. 31, 360\u2013372 (2025).","journal-title":"Clin. Microbiol. Infect."},{"key":"671_CR126","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1001\/jamainternmed.2024.8124","volume":"185","author":"Y Liu","year":"2025","unstructured":"Liu, Y. & Parks, A. L. Diagnosis and management of monoclonal gammopathy of undetermined significance: a review. JAMA Intern. Med. 185, 450\u2013456 (2025).","journal-title":"JAMA Intern. Med."},{"key":"671_CR127","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1007\/s00467-024-06278-9","volume":"39","author":"L Obrycki","year":"2024","unstructured":"Obrycki, L. et al. Kidney volume normative values in Central European children aged 0\u201319 years: a multicenter study. Pediatr. Nephrol. 39, 2147\u20132159 (2024).","journal-title":"Pediatr. Nephrol."},{"key":"671_CR128","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1093\/ndt\/gfae238","volume":"40","author":"KV De Santiago-Rodriguez","year":"2025","unstructured":"De Santiago-Rodriguez, K. V. et al. Association of perinatal exposition to xenobiotics with kidney volume at birth. Nephrol. Dial. Transplant. 40, 1007\u20131019 (2025).","journal-title":"Nephrol. Dial. Transplant."},{"key":"671_CR129","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14100994","volume":"14","author":"RM Steflea","year":"2024","unstructured":"Steflea, R. M. et al. A pilot comparative study between creatinine- and cystatin-C-based equations to estimate GFR and kidney ultrasound percentiles in children with congenital anomalies of the kidney and urinary tract. Diagnostics 14, 994 (2024).","journal-title":"Diagnostics"},{"key":"671_CR130","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1093\/ndt\/16.suppl_6.74","volume":"16","author":"AB Fogo","year":"2001","unstructured":"Fogo, A. B. Minimal change disease and focal segmental glomerulosclerosis. Nephrol. Dial. Transpl. 16, 74\u201376 (2001).","journal-title":"Nephrol. Dial. Transpl."},{"key":"671_CR131","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.kint.2023.03.013","volume":"103","author":"D Unnersjo-Jess","year":"2023","unstructured":"Unnersjo-Jess, D. et al. Deep learning-based segmentation and quantification of podocyte foot process morphology suggests differential patterns of foot process effacement across kidney pathologies. Kidney Int. 103, 1120\u20131130 (2023).","journal-title":"Kidney Int."},{"key":"671_CR132","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.3899\/jrheum.170689","volume":"44","author":"M Navratil","year":"2017","unstructured":"Navratil, M. & Ivkovic Jurekovic, I. Chloroquine toxicity misdiagnosed as Fabry disease associated with systemic lupus erythematosus and Hashimoto thyroiditis. J. Rheumatol. 44, 1940 (2017).","journal-title":"J. Rheumatol."},{"key":"671_CR133","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/S0140-6736(23)00876-0","volume":"402","author":"D van Mil","year":"2023","unstructured":"van Mil, D. et al. Participation rate and yield of two home-based screening methods to detect increased albuminuria in the general population in the Netherlands (THOMAS): a prospective, randomised, open-label implementation study. Lancet 402, 1052\u20131064 (2023).","journal-title":"Lancet"},{"key":"671_CR134","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S0140-6736(23)01140-6","volume":"402","author":"JA Lamprea-Montealegre","year":"2023","unstructured":"Lamprea-Montealegre, J. A. & Estrella, M. M. Population-wide albuminuria screening: implications for CKD detection and management. Lancet 402, 1020\u20131021 (2023).","journal-title":"Lancet"},{"key":"671_CR135","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.kint.2025.04.005","volume":"108","author":"A Ortiz","year":"2025","unstructured":"Ortiz, A. et al. Preventing chronic kidney disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 108, 555\u2013571 (2025).","journal-title":"Kidney Int."},{"key":"671_CR136","doi-asserted-by":"publisher","unstructured":"Romagnani, P., Chan, J. C. N. & Anders H.-J. Multifactorial chronic kidney disease and the kidney capacity\u2013workload balance. Nat. Rev. Nephrol. https:\/\/doi.org\/10.1038\/s41581-025-01038-w (2026).","DOI":"10.1038\/s41581-025-01038-w"},{"key":"671_CR137","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1053\/j.ajkd.2020.04.014","volume":"77","author":"JP Troost","year":"2021","unstructured":"Troost, J. P. et al. Proteinuria reduction and kidney survival in focal segmental glomerulosclerosis. Am. J. Kidney Dis. 77, 216\u2013225 (2021).","journal-title":"Am. J. Kidney Dis."},{"key":"671_CR138","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza, F. C. et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N. Engl. J. Med. 381, 36\u201346 (2019).","journal-title":"N. Engl. J. Med."},{"key":"671_CR139","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae243","volume":"17","author":"NM Tomas","year":"2024","unstructured":"Tomas, N. M. Therapeutic targets in membranous nephropathy: plasma cells and complement. Clin. Kidney J. 17, sfae243 (2024).","journal-title":"Clin. Kidney J."},{"key":"671_CR140","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1681\/ASN.0000000520","volume":"36","author":"P Gauckler","year":"2025","unstructured":"Gauckler, P. et al. Long-term outcomes of rituximab-treated adult patients with podocytopathies. J. Am. Soc. Nephrol. 36, 668\u2013678 (2025).","journal-title":"J. Am. Soc. Nephrol."},{"key":"671_CR141","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","volume":"172","author":"B Basu","year":"2018","unstructured":"Basu, B. et al. Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial. JAMA Pediatr. 172, 757\u2013764 (2018).","journal-title":"JAMA Pediatr."},{"key":"671_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.06.2120","author":"C Tur","year":"2025","unstructured":"Tur, C. et al. Effects of different B-cell-depleting strategies on the lymphatic tissue. Ann. Rheum. Dis. https:\/\/doi.org\/10.1016\/j.ard.2025.06.2120 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"671_CR143","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/ndt\/gfad265","volume":"39","author":"G Trivioli","year":"2024","unstructured":"Trivioli, G., Peyronel, F. & Vaglio, A. The new generation of B cell-targeting therapies for the treatment of autoimmune kidney diseases. Nephrol. Dial. Transpl. 39, 1210\u20131213 (2024).","journal-title":"Nephrol. Dial. Transpl."},{"key":"671_CR144","volume":"14","author":"C Sessa","year":"2025","unstructured":"Sessa, C. et al. Obinutuzumab in membranous nephropathy: a potential game-changer in treatment. Drugs Context. 14, 2024-9-1 (2025).","journal-title":"Drugs Context."},{"key":"671_CR145","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2215\/CJN.0000000000000288","volume":"18","author":"C Dossier","year":"2023","unstructured":"Dossier, C. et al. Obinutuzumab in frequently relapsing and steroid-dependent nephrotic syndrome in children. Clin. J. Am. Soc. Nephrol. 18, 1555\u20131562 (2023).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"671_CR146","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.2215\/CJN.0000000000000555","volume":"19","author":"X Hu","year":"2024","unstructured":"Hu, X. et al. Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy. Clin. J. Am. Soc. Nephrol. 19, 1594\u20131602 (2024).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"671_CR147","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00467-024-06570-8","volume":"40","author":"EY Chan","year":"2025","unstructured":"Chan, E. Y. et al. Obinutuzumab as a viable therapeutic strategy in rituximab-refractory childhood frequently relapsing, steroid-dependent nephrotic syndrome that relapsed during B-cell depletion. Pediatr. Nephrol. 40, 711\u2013714 (2025).","journal-title":"Pediatr. Nephrol."},{"key":"671_CR148","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1182\/bloodadvances.2022009548","volume":"7","author":"T Schieber","year":"2023","unstructured":"Schieber, T. et al. Successful obinutuzumab administration after rituximab discontinuation due to intolerance in patients with hematologic disorders. Blood Adv. 7, 3431\u20133434 (2023).","journal-title":"Blood Adv."},{"key":"671_CR149","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s00467-021-05304-4","volume":"37","author":"Y Inoki","year":"2022","unstructured":"Inoki, Y. et al. Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome. Pediatr. Nephrol. 37, 1057\u20131066 (2022).","journal-title":"Pediatr. Nephrol."},{"key":"671_CR150","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1007\/s00467-023-05913-1","volume":"38","author":"A Zurowska","year":"2023","unstructured":"Zurowska, A. et al. Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey. Pediatr. Nephrol. 38, 3035\u20133042 (2023).","journal-title":"Pediatr. Nephrol."},{"key":"671_CR151","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood-2018-04-848044","volume":"133","author":"S Kusumoto","year":"2019","unstructured":"Kusumoto, S. et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood 133, 137\u2013146 (2019).","journal-title":"Blood"},{"key":"671_CR152","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","volume":"83","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 83, 502\u2013583 (2025).","journal-title":"J. Hepatol."},{"key":"671_CR153","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1681\/ASN.2020101541","volume":"32","author":"L Zand","year":"2021","unstructured":"Zand, L. et al. Safety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits. J. Am. Soc. Nephrol. 32, 1163\u20131173 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"671_CR154","doi-asserted-by":"publisher","first-page":"e579","DOI":"10.1016\/j.clml.2020.04.004","volume":"20","author":"S Al Hadidi","year":"2020","unstructured":"Al Hadidi, S. et al. Safety analysis of five randomized controlled studies of daratumumab in patients with multiple myeloma. Clin. Lymphoma Myeloma Leuk. 20, e579\u2013e589 (2020).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"671_CR155","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.ekir.2024.04.006","volume":"9","author":"A Angeletti","year":"2024","unstructured":"Angeletti, A. et al. Combined rituximab and daratumumab treatment in difficult-to-treat nephrotic syndrome cases. Kidney Int. Rep. 9, 1892\u20131896 (2024).","journal-title":"Kidney Int. Rep."},{"key":"671_CR156","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109\u2013121 (2024). This study provides proof of concept that treating obesity can improve adaptive podocytopathies and slow CKD progression in diabetes mellitus.","journal-title":"N. Engl. J. Med."},{"key":"671_CR157","first-page":"389","volume":"384","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink, H. J. L., Langkilde, A. M. & Wheeler, D. C. Dapagliflozin in patients with chronic kidney disease. Reply. N. Engl. J. Med. 384, 389\u2013390 (2021). This study provides the key evidence of beneficial effects of SGLT2 blockade in patients with non-diabetic forms of CKD associated with proteinuria.","journal-title":"N. Engl. J. Med."},{"key":"671_CR158","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa2409183","volume":"392","author":"EMPA-KIDNEY Collaborative Group","year":"2025","unstructured":"EMPA-KIDNEY Collaborative Group Long-term effects of empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 392, 777\u2013787 (2025).","journal-title":"N. Engl. J. Med."},{"key":"671_CR159","doi-asserted-by":"publisher","DOI":"10.7326\/J23-0001","volume":"176","author":"D Molony","year":"2023","unstructured":"Molony, D., Horvit, A. & Waguespack, D. In advanced progressive CKD, discontinuing RAS inhibitors did not improve eGFR at 3 y. Ann. Intern. Med. 176, JC28 (2023).","journal-title":"Ann. Intern. Med."},{"key":"671_CR160","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12325-021-02006-z","volume":"39","author":"JJ Garcia Sanchez","year":"2022","unstructured":"Garcia Sanchez, J. J. et al. Treatments for chronic kidney disease: a systematic literature review of randomized controlled trials. Adv. Ther. 39, 193\u2013220 (2022).","journal-title":"Adv. Ther."},{"key":"671_CR161","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","volume":"387","author":"S Bhandari","year":"2022","unstructured":"Bhandari, S. et al. Renin-angiotensin system inhibition in advanced chronic kidney disease. N. Engl. J. Med. 387, 2021\u20132032 (2022).","journal-title":"N. Engl. J. Med."},{"key":"671_CR162","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2215\/CJN.09380822","volume":"18","author":"BF Palmer","year":"2023","unstructured":"Palmer, B. F. & Clegg, D. J. Kidney-protective effects of SGLT2 inhibitors. Clin. J. Am. Soc. Nephrol. 18, 279\u2013289 (2023).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"671_CR163","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf197","author":"MJ Vargas-Brochero","year":"2025","unstructured":"Vargas-Brochero, M. J. et al. Antiproteinuric effect of SGLT2 inhibitors in non-diabetic glomerulopathies is dependent on body mass index. Nephrol. Dial. Transpl. https:\/\/doi.org\/10.1093\/ndt\/gfaf197 (2025).","journal-title":"Nephrol. Dial. Transpl."},{"key":"671_CR164","doi-asserted-by":"publisher","DOI":"10.3390\/biom12010143","volume":"12","author":"C Llorens-Cebria","year":"2022","unstructured":"Llorens-Cebria, C. et al. Antioxidant roles of SGLT2 inhibitors in the kidney. Biomolecules 12, 143 (2022).","journal-title":"Biomolecules"},{"key":"671_CR165","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","volume":"62","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink, H. J. L. et al. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia 62, 1154\u20131166 (2019).","journal-title":"Diabetologia"},{"key":"671_CR166","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","volume":"145","author":"BL Neuen","year":"2022","unstructured":"Neuen, B. L. et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation 145, 1460\u20131470 (2022).","journal-title":"Circulation"},{"key":"671_CR167","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/jcmm.17115","volume":"26","author":"Q Tian","year":"2022","unstructured":"Tian, Q. et al. Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: a meta-analysis. J. Cell Mol. Med. 26, 540\u2013547 (2022).","journal-title":"J. Cell Mol. Med."},{"key":"671_CR168","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1093\/ndt\/gfae032","volume":"39","author":"C Wanner","year":"2024","unstructured":"Wanner, C. et al. How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG outcome trial. Nephrol. Dial. Transpl. 39, 1504\u20131513 (2024).","journal-title":"Nephrol. Dial. Transpl."},{"key":"671_CR169","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1125693","volume":"14","author":"R Lv","year":"2023","unstructured":"Lv, R. et al. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus. Front. Endocrinol. 14, 1125693 (2023).","journal-title":"Front. Endocrinol."},{"key":"671_CR170","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2025.108981","volume":"39","author":"R Liu","year":"2025","unstructured":"Liu, R. et al. Progress in the treatment of vascular complications in type 2 diabetes by finerenone in combination with RAS inhibitors\/SGLT-2i. J. Diabetes Complications 39, 108981 (2025).","journal-title":"J. Diabetes Complications"},{"key":"671_CR171","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/ndt\/gfae132","volume":"40","author":"HJL Heerspink","year":"2025","unstructured":"Heerspink, H. J. L. et al. Design and baseline characteristics of the finerenone, in addition to standard of care, on the progression of kidney disease in patients with non-diabetic chronic kidney disease (FIND-CKD) randomized trial. Nephrol. Dial. Transpl. 40, 308\u2013319 (2025).","journal-title":"Nephrol. Dial. Transpl."},{"key":"671_CR172","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","volume":"393","author":"R Agarwal","year":"2025","unstructured":"Agarwal, R. et al. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N. Engl. J. Med. 393, 533\u2013543 (2025). This study shows that combining finerenone with empagliflozin provides additive kidney and cardiovascular protection in patients with CKD and type 2 diabetes mellitus, defining a new dual-blockade treatment paradigm.","journal-title":"N. Engl. J. Med."},{"key":"671_CR173","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1148209","volume":"14","author":"SF Mehdi","year":"2023","unstructured":"Mehdi, S. F. et al. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front. Immunol. 14, 1148209 (2023).","journal-title":"Front. Immunol."},{"key":"671_CR174","doi-asserted-by":"publisher","first-page":"F1010","DOI":"10.1152\/ajprenal.00028.2019","volume":"317","author":"K Katsurada","year":"2019","unstructured":"Katsurada, K. et al. Does glucagon-like peptide-1 induce diuresis and natriuresis by modulating afferent renal nerve activity? Am. J. Physiol. Ren. Physiol. 317, F1010\u2013F1021 (2019).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"671_CR175","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa2308550","volume":"389","author":"MN Rheault","year":"2023","unstructured":"Rheault, M. N. et al. Sparsentan versus irbesartan in focal segmental glomerulosclerosis. N. Engl. J. Med. 389, 2436\u20132445 (2023).","journal-title":"N. Engl. J. Med."},{"key":"671_CR176","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/study\/NCT04573920 (2025)."},{"key":"671_CR177","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/study\/NCT05237388 (2025)."},{"key":"671_CR178","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/study\/NCT05213624 (2025)."},{"key":"671_CR179","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/study\/NCT05448755 (2022)."},{"key":"671_CR180","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/study\/NCT05183646 (2025)."},{"key":"671_CR181","doi-asserted-by":"publisher","first-page":"i59","DOI":"10.1093\/ndt\/gfae258","volume":"40","author":"BL Neuen","year":"2025","unstructured":"Neuen, B. L. et al. Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease. Nephrol. Dial. Transpl. 40, i59\u2013i69 (2025).","journal-title":"Nephrol. Dial. Transpl."},{"key":"671_CR182","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1056\/NEJMoa2202396","volume":"388","author":"O Egbuna","year":"2023","unstructured":"Egbuna, O. et al. Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants. N. Engl. J. Med. 388, 969\u2013979 (2023).","journal-title":"N. Engl. J. Med."},{"key":"671_CR183","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng, C. M. et al. Safety and efficacy of recombinant human \u03b1-galactosidase A replacement therapy in Fabry\u2019s disease. N. Engl. J. Med. 345, 9\u201316 (2001).","journal-title":"N. Engl. J. Med."},{"key":"671_CR184","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1306","volume":"8","author":"H Deng","year":"2020","unstructured":"Deng, H. et al. Phenotypic spectrum and antialbuminuric response to angiotensin converting enzyme inhibitor and angiotensin receptor blocker therapy in pediatric Dent disease. Mol. Genet. Genom. Med. 8, e1306 (2020).","journal-title":"Mol. Genet. Genom. Med."},{"key":"671_CR185","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc8226","volume":"15","author":"WY Ding","year":"2023","unstructured":"Ding, W. Y. et al. Adeno-associated virus gene therapy prevents progression of kidney disease in genetic models of nephrotic syndrome. Sci. Transl. Med. 15, eabc8226 (2023). This study provides proof of concept that AAV-based gene therapy can halt progression of genetic nephrotic syndromes, opening a path towards gene therapy of podocytopathies.","journal-title":"Sci. Transl. Med."},{"key":"671_CR186","doi-asserted-by":"publisher","DOI":"10.1172\/JCI174722","volume":"134","author":"G Wu","year":"2024","unstructured":"Wu, G. et al. Adeno-associated virus-based gene therapy treats inflammatory kidney disease in mice. J. Clin. Invest. 134, e174722 (2024).","journal-title":"J. Clin. Invest."},{"key":"671_CR187","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/ndt\/gfad067","volume":"38","author":"P Romagnani","year":"2023","unstructured":"Romagnani, P. et al. The five types of glomerulonephritis classified by pathogenesis, activity and chronicity (GN-AC). Nephrol. Dial. Transpl. 38, ii3\u2013ii10 (2023).","journal-title":"Nephrol. Dial. Transpl."},{"key":"671_CR188","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104040","volume":"187","author":"BA Costa","year":"2023","unstructured":"Costa, B. A. et al. Revisiting the role of alkylating agents in multiple myeloma: up-to-date evidence and future perspectives. Crit. Rev. Oncol. Hematol. 187, 104040 (2023).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"671_CR189","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1124\/mol.119.118653","volume":"97","author":"Y Fan","year":"2020","unstructured":"Fan, Y. & You, G. Proteasome inhibitors bortezomib and carfilzomib stimulate the transport activity of human organic anion transporter 1. Mol. Pharmacol. 97, 384\u2013391 (2020).","journal-title":"Mol. Pharmacol."},{"key":"671_CR190","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1382977","volume":"15","author":"Z Chen","year":"2024","unstructured":"Chen, Z., Xu, Q. & Shou, Z. Application of CD38 monoclonal antibody in kidney disease. Front. Immunol. 15, 1382977 (2024).","journal-title":"Front. Immunol."},{"key":"671_CR191","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112948","volume":"15","author":"S More","year":"2023","unstructured":"More, S. et al. Belantamab mafodotin: from clinical trials data to real-life experiences. Cancers 15, 2948 (2023).","journal-title":"Cancers"},{"key":"671_CR192","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1182\/bloodadvances.2020002524","volume":"4","author":"SF Cho","year":"2020","unstructured":"Cho, S. F. et al. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 4, 4195\u20134207 (2020).","journal-title":"Blood Adv."},{"key":"671_CR193","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Working Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Working Group KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 105, S117\u2013S314 (2024).","journal-title":"Kidney Int."},{"key":"671_CR194","doi-asserted-by":"publisher","DOI":"10.1111\/apha.14183","volume":"240","author":"A Schork","year":"2024","unstructured":"Schork, A. et al. Amiloride versus furosemide for the treatment of edema in patients with nephrotic syndrome: a pilot study (AMILOR). Acta Physiol. 240, e14183 (2024).","journal-title":"Acta Physiol."},{"key":"671_CR195","doi-asserted-by":"publisher","first-page":"641","DOI":"10.26574\/maedica.2024.19.3.641","volume":"19","author":"VG Fratila","year":"2024","unstructured":"Fratila, V. G. et al. Combination of diuretics in states of resistant nephrotic edema: a case presentation. Maedica 19, 641\u2013647 (2024).","journal-title":"Maedica"},{"key":"671_CR196","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9091078","volume":"9","author":"R Fiorentino","year":"2021","unstructured":"Fiorentino, R. & Chiarelli, F. Treatment of dyslipidaemia in children. Biomedicines 9, 1078 (2021).","journal-title":"Biomedicines"},{"key":"671_CR197","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.120479","author":"F Mach","year":"2025","unstructured":"Mach, F. et al. 2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias. Eur. Heart J. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120479 (2025).","journal-title":"Eur. Heart J."},{"key":"671_CR198","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1339487","volume":"11","author":"I Mercep","year":"2024","unstructured":"Mercep, I. et al. PCSK9 inhibition: from effectiveness to cost-effectiveness. Front. Cardiovasc. Med. 11, 1339487 (2024).","journal-title":"Front. Cardiovasc. Med."},{"key":"671_CR199","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4103\/2229-5151.183019","volume":"6","author":"HF Al-Azzawi","year":"2016","unstructured":"Al-Azzawi, H. F. et al. Nephrotic syndrome-induced thromboembolism in adults. Int. J. Crit. Illn. Inj. Sci. 6, 85\u201388 (2016).","journal-title":"Int. J. Crit. Illn. Inj. Sci."},{"key":"671_CR200","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00467-013-2525-5","volume":"29","author":"BA Kerlin","year":"2014","unstructured":"Kerlin, B. A., Haworth, K. & Smoyer, W. E. Venous thromboembolism in pediatric nephrotic syndrome. Pediatr. Nephrol. 29, 989\u2013997 (2014).","journal-title":"Pediatr. Nephrol."},{"key":"671_CR201","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ekir.2019.12.001","volume":"5","author":"R Lin","year":"2020","unstructured":"Lin, R. et al. A systematic review of prophylactic anticoagulation in nephrotic syndrome. Kidney Int. Rep. 5, 435\u2013447 (2020).","journal-title":"Kidney Int. Rep."},{"key":"671_CR202","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1177\/0009922820908583","volume":"59","author":"A Lebel","year":"2020","unstructured":"Lebel, A. et al. Infections in children with nephrotic syndrome: twenty years of experience. Clin. Pediatr. 59, 692\u2013698 (2020).","journal-title":"Clin. Pediatr."},{"key":"671_CR203","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.711637","volume":"12","author":"G Blanchard-Rohner","year":"2021","unstructured":"Blanchard-Rohner, G. Vaccination in children with autoimmune disorders and treated with various immunosuppressive regimens: a comprehensive review and practical guide. Front. Immunol. 12, 711637 (2021).","journal-title":"Front. Immunol."},{"key":"671_CR204","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-02644-x","volume":"11","author":"S Ishimori","year":"2021","unstructured":"Ishimori, S. et al. Influenza virus vaccination in pediatric nephrotic syndrome significantly reduces rate of relapse and influenza virus infection as assessed in a nationwide survey. Sci. Rep. 11, 23305 (2021).","journal-title":"Sci. Rep."},{"key":"671_CR205","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2215\/CJN.01890221","volume":"16","author":"A Angeletti","year":"2021","unstructured":"Angeletti, A. et al. Vaccines and disease relapses in children with nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 16, 937\u2013938 (2021).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"671_CR206","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1111\/ajt.17077","volume":"22","author":"M Hattori","year":"2022","unstructured":"Hattori, M. et al. Circulating nephrin autoantibodies and posttransplant recurrence of primary focal segmental glomerulosclerosis. Am. J. Transpl. 22, 2478\u20132480 (2022).","journal-title":"Am. J. Transpl."},{"key":"671_CR207","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/j.1600-6143.2008.02237.x","volume":"8","author":"TS Dabade","year":"2008","unstructured":"Dabade, T. S. et al. Recurrent idiopathic membranous nephropathy after kidney transplantation: a surveillance biopsy study. Am. J. Transpl. 8, 1318\u20131322 (2008).","journal-title":"Am. J. Transpl."},{"key":"671_CR208","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2215\/CJN.08970719","volume":"15","author":"A Uffing","year":"2020","unstructured":"Uffing, A. et al. Recurrence of FSGS after kidney transplantation in adults. Clin. J. Am. Soc. Nephrol. 15, 247\u2013256 (2020).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"671_CR209","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1681\/ASN.2013080852","volume":"25","author":"WY Ding","year":"2014","unstructured":"Ding, W. Y. et al. Initial steroid sensitivity in children with steroid-resistant nephrotic syndrome predicts post-transplant recurrence. J. Am. Soc. Nephrol. 25, 1342\u20131348 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"671_CR210","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/tri.13372","volume":"32","author":"N Puig-Gay","year":"2019","unstructured":"Puig-Gay, N. et al. Apolipoprotein A-Ib as a biomarker of focal segmental glomerulosclerosis recurrence after kidney transplantation: diagnostic performance and assessment of its prognostic value \u2014 a multi-centre cohort study. Transpl. Int. 32, 313\u2013322 (2019).","journal-title":"Transpl. Int."},{"key":"671_CR211","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100826","volume":"6","author":"M Bonilla","year":"2024","unstructured":"Bonilla, M. et al. A review of focal segmental glomerulosclerosis classification with a focus on genetic associations. Kidney Med. 6, 100826 (2024).","journal-title":"Kidney Med."},{"key":"671_CR212","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00467-015-3074-x","volume":"30","author":"DT Selewski","year":"2015","unstructured":"Selewski, D. T. et al. The impact of disease duration on quality of life in children with nephrotic syndrome: a Midwest Pediatric Nephrology Consortium study. Pediatr. Nephrol. 30, 1467\u20131476 (2015).","journal-title":"Pediatr. Nephrol."},{"key":"671_CR213","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.745444","volume":"9","author":"N Li","year":"2021","unstructured":"Li, N. et al. Evaluating the quality of life of 231 children with primary nephrotic syndrome and assessing parental awareness of the disease. Front. Pediatr. 9, 745444 (2021).","journal-title":"Front. Pediatr."},{"key":"671_CR214","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s40620-021-01111-0","volume":"35","author":"MS Meuleman","year":"2022","unstructured":"Meuleman, M. S. et al. Long-term health-related quality of life outcomes of adults with pediatric onset of frequently relapsing or steroid-dependent nephrotic syndrome. J. Nephrol. 35, 1123\u20131134 (2022).","journal-title":"J. Nephrol."},{"key":"671_CR215","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/124315","volume":"2013","author":"Y Shutto","year":"2013","unstructured":"Shutto, Y., Yamabe, H., Shimada, M., Fujita, T. & Nakamura, N. Quality of life in patients with minimal change nephrotic syndrome. ScientificWorldJournal 2013, 124315 (2013).","journal-title":"ScientificWorldJournal"},{"key":"671_CR216","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.xkme.2021.01.013","volume":"3","author":"NE Carlozzi","year":"2021","unstructured":"Carlozzi, N. E. et al. Health-related quality of life in focal segmental glomerular sclerosis and minimal change disease: a qualitative study of children and adults to inform patient-reported outcomes. Kidney Med. 3, 484\u2013497.e1 (2021).","journal-title":"Kidney Med."},{"key":"671_CR217","doi-asserted-by":"publisher","DOI":"10.1177\/2054358119898016","volume":"7","author":"CI Esezobor","year":"2020","unstructured":"Esezobor, C. I., Solarin, A. U. & Olagunju, A. T. Significant burden and psychological distress among caregivers of children with nephrotic syndrome: a cross-sectional study. Can. J. Kidney Health Dis. 7, 2054358119898016 (2020).","journal-title":"Can. J. Kidney Health Dis."},{"key":"671_CR218","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.34067\/KID.0005072021","volume":"3","author":"CA Simon","year":"2022","unstructured":"Simon, C. A. et al. The health economic impact of nephrotic syndrome in the United States. Kidney360 3, 1073\u20131079 (2022).","journal-title":"Kidney360"},{"key":"671_CR219","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00467-017-3789-y","volume":"33","author":"F Iorember","year":"2018","unstructured":"Iorember, F. et al. Cost analysis on the use of rituximab and calcineurin inhibitors in children and adolescents with steroid-dependent nephrotic syndrome. Pediatr. Nephrol. 33, 261\u2013267 (2018).","journal-title":"Pediatr. Nephrol."},{"key":"671_CR220","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.4065\/81.10.1361","volume":"81","author":"T Warrington","year":"2006","unstructured":"Warrington, T. & Bostwick, J. M. Psychiatric adverse effects of corticosteroids. Mayo Clin. Proc. 81, 1361\u20131367 (2006).","journal-title":"Mayo Clin. Proc."},{"key":"671_CR221","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/ki.2011.195","volume":"80","author":"DS Gipson","year":"2011","unstructured":"Gipson, D. S. et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 80, 868\u2013878 (2011).","journal-title":"Kidney Int."},{"key":"671_CR222","unstructured":"Clinical Trials Arena. FDA confirms primary goal for Dimerix\u2019s DMX-200 trial to treat FSGS. Clinical Trials Arena https:\/\/www.clinicaltrialsarena.com\/news\/fda-dimerix-trial\/ (2025)."},{"key":"671_CR223","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00467-014-2781-z","volume":"29","author":"C Holmberg","year":"2014","unstructured":"Holmberg, C. & Jalanko, H. Congenital nephrotic syndrome and recurrence of proteinuria after renal transplantation. Pediatr. Nephrol. 29, 2309\u20132317 (2014).","journal-title":"Pediatr. Nephrol."}],"container-title":["Nature Reviews Disease Primers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41572-025-00671-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-025-00671-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-025-00671-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T08:03:07Z","timestamp":1765440187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41572-025-00671-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":223,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["671"],"URL":"https:\/\/doi.org\/10.1038\/s41572-025-00671-w","relation":{},"ISSN":["2056-676X"],"issn-type":[{"value":"2056-676X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"11 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Related to the content of this paper, P.R. is inventor on patent PCT\/IB2024\/060751 (status: filed; relating to the assessment of anti-podocin and anti-Kirrel1 antibodies for the diagnosis of nephrotic syndrome; inventors: P. Romagnani, L. De Chiara, M. L. Angelotti, V. Raglianti, M. E. Melica and B. Mazzinghi; patent owners: University of Florence and Meyer Children\u2019s Hospital IRCCS); and is a member of the ISGD Steering Committee and of the ERKNet group. S.C.W.T. reports honoraria and advisory fees received from: AstraZeneca, Bayer, Boehringer-Ingelheim, GSK and Novartis Pharma AG; is a member of the KDIGO Executive Committee 2020-2023; is a core member of IgAN Clinical Practice Guideline Work Group 2024; and is co-chair of Peer support Group, ISGD. T.B.H. reports consultancy agreements with Alexion, AstraZeneca, Bayer, Beren Therapeutics, Boehringer-Ingelheim, DaVita, Euroimmune, Fresenius Medical Care, Nipoka, Novartis, Pfizer, Renovate, Retrophin-Travere, Sanofi, Vera Therapeutics, Vifor and Vivoryon; reports research funding from Amicus Therapeutics, Fresenius Medical Care and Euroimmune; is co-founder of Global Immune GmbH; and is inventor on patent 3\/2024 PAT 1878 LU (status: filed; title: \u201cMethod for the detection of antibodies\u201d, which relates to the technological basis of reference\n                      43\n                      ; inventors: F. Hengel, S. Dehde, N. Tomas, T. B. Huber; applicant: University Medical Center Hamburg Eppendorf). A.W. received consultancies from Sysmex and Vera Therapeutics and travel support from Genentech; and is inventor on patent PCT\/US2021\/056157 (status: granted; title: \u201cMethods for identifying and treating antibody-mediated acquired primary or recurrent idiopathic nephrotic syndrome\u201d; inventors: A. Weins, H. G. Rennke, J. M. Henderson, A. Watts, K. Keller; applicants: The Brigham and Women\u2019s Hospital, Inc. and Boston Medical Center Corporation). H.-J.A. received consultancy fees from Novartis, AstraZeneca, Boehringer-Ingelheim, CSL Vifor, Otsuka and Roche; received payments from the European Renal Association for his role as Editor-in-Chief of\n                      Nephrology Dialysis Transplantation\n                      ; and is a member of the Western-European Regional board of the International Society of Nephrology (ISN).\u00a0C.O. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}